Valuing Genzyme: Adding A Health Care Reform Premium
Executive Summary
As Sanofi-Aventis's board mulls whether to up its offer for Genzyme, Wall Street is busy crunching the numbers, and there are plenty of factors to consider. Sanofi’s now-public offer is $69 per share in cash, or a total of $18.5 billion for the company. That represents about a 40% premium to Genzyme Corp.’s share price as of mid-July, when Sanofi’s interest became apparent.